Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial
Clayton AH, Althof SE, Kingsberg S, et al. (2016). Women's Health.
Summary
The phase 2b dose-finding trial that set up the phase 3 programme. Premenopausal women with female sexual dysfunction self-administered bremelanotide or placebo subcutaneously as desired over 12 weeks. Pooling the two higher bremelanotide groups against placebo, the number of satisfying sexual events per month rose by about half an event more than placebo, with improvements on the Female Sexual Function Index and the associated distress scale. Reported adverse events were nausea, flushing and headache.